MedGene Therapeutics Publishes Preclinical Data Demonstrating RIV-8’s Ability to Overcome T Cell Exhaustion in the Journal Science Advances
29 nov. 2022 17h00 HE
|
Medgene Therapeutics, Inc.
GAITHERSBURG, Md., Nov. 29, 2022 (GLOBE NEWSWIRE) -- MedGene Therapeutics, Inc. (MedGene), a biopharmaceutical company dedicated to bringing adoptive cell therapies to solid tumors, today announced...